Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nadunolimab + gemcitabine + cisplatin
- Development stage
- Unknown
- Lead developer
- Cantargia
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Nadunolimab + gemcitabine + cisplatin is a combination regimen for cancer therapy. **Nadunolimab** is a fully humanized monoclonal antibody that targets IL1RAP (IL-1 receptor accessory protein), blocking IL-1α/IL-1β signaling to disrupt tumor-promoting inflammation and enhance anti-tumor immune response. It induces antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis, particularly by engaging NK cells and macrophages[2][6][8]. **Gemcitabine** and **cisplatin** are standard cytotoxic chemotherapies; gemcitabine is a nucleoside analog that inhibits DNA synthesis, and cisplatin induces DNA crosslinking and apoptosis. This combination is principally investigated in advanced or metastatic cancers, including non-small cell lung cancer (NSCLC) and biliary tract cancer. Clinical trials report promising efficacy with manageable safety in heavily pre-treated and chemo-naive patients[1][3][5].
- Brand names
- nadunolimab
- Other names
- nadunolimab + gemcitabine + cisplatin
02
Targets
IL1RAP (Interleukin 1 receptor accessory protein)
Beyond the preview
Go deeper on nadunolimab + gemcitabine + cisplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nadunolimab + gemcitabine + cisplatin.